← Coya Therapeutics, Inc. (COYA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Coya Therapeutics, Inc. (COYA)
Pharmaceutical Preparations · market cap $120M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
1
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Coya Therapeutics (COYA) is a micro-cap pharmaceutical company with 8 employees and a $123M market cap, developing COYA 302 for ALS in a Phase 2 trial. The next major catalyst is an estimated Phase 2 data readout in January 2027, with an earnings report due August 2026. The company holds $50.7M in cash with approximately 24.5 months of runway, providing a buffer through the anticipated data readout.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-01-15 (est.)Phase 3 · COYA 302imp 9/10
- 2027-01-15 (est.)Phase 2 · COYA 302imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| COYA 302 | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) |
Price & technical context
3-month
-19.3%
6-month
+15.9%
12-month
-17.0%
52-wk range
$3.78–$7.36
vs 50-day MA
+1.2%
vs 200-day MA
-0.3%
Realized vol
63.9%
Max drawdown
-62.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for COYA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.